.
A TeneoBio cancer drug is showing early encouraging indications of efficacy in medical testing and AbbVie likes the outcomes enough to exercise its alternative to acquire it, giving the pharmaceutical giant a method to keep up in the chase to hit a hot protein target for multiple myeloma.
AbbVie is paying an undisclosed amount to acquire TeneoOne, the affiliate of Newark, California-based TeneoBio that is developing the drug, TNB-383B. In 2019, the North Chicago-based pharmaceutical giant paid $90 million in advance for a special alternative to get TeneoOne, which was responsible for developing the drug through Phase 1 screening.
Several business are aiming to deal with the illness with drugs that hit B-cell maturation antigen (BCMA), a protein thats discovered in abundance on multiple myeloma cells. The drug is developed to direct the immune system to target the growths that express BCMA.
A Phase 1 dose-escalation test of TNB-383B is ongoing, however according to interim results reported by AbbVie and TeneoBio in 103 patients, treatment with the drug led to a 79% total action rate. The most frequent adverse events reported in the study included an immune response called cytokine release syndrome, tiredness, and an unusually low levels of a type of white blood cell called a neutrophil.
That drug is an antibody drug conjugate, a type of drug that connects a tumor-killing payload to a targeting antibody. Amgens BCMA-targeting drug prospect is a bispecific T cell engager.
The GSK and BMS numerous myeloma drugs were each authorized for dealing with clients whose disease has actually not reacted to 4 lines of treatment. AbbVie plans to establish TNB-383B for those who have actually had 3 earlier treatments. The company also sees the intravenously administered TeneoBio drug as offering a benefit of less frequent dosing. Other BCMA and CD3 bispecific therapies need to be offered weekly. In a ready declaration, Michael Severino, vice chairman and president of AbbVie, said that the Phase 2 scientific trial for TNB-383B will evaluate a 60 mg dosage offered every three weeks.
Photo by AbbVie.

Several companies are aiming to treat the disease with drugs that strike B-cell maturation antigen (BCMA), a protein thats found in abundance on numerous myeloma cells. A Phase 1 dose-escalation test of TNB-383B is continuous, but according to interim outcomes reported by AbbVie and TeneoBio in 103 patients, treatment with the drug led to a 79% overall action rate. That drug is an antibody drug conjugate, a type of drug that connects a tumor-killing payload to a targeting antibody. Amgens BCMA-targeting drug candidate is a bispecific T cell engager.